Zur Kurzanzeige

dc.creatorStamatis P., Turkiewicz A., Englund M., Turesson C., Mohammad A.J.en
dc.date.accessioned2023-01-31T10:02:05Z
dc.date.available2023-01-31T10:02:05Z
dc.date.issued2022
dc.identifier10.1093/rheumatology/keab269
dc.identifier.issn14620324
dc.identifier.urihttp://hdl.handle.net/11615/79373
dc.description.abstractObjective: To characterize the epidemiology of temporal artery biopsy-positive (TAB+) GCA, including trends in incidence, seasonal variation and prevalence in Skåne, the southernmost region of Sweden. Methods: All histopathology reports of TABs from 1997 through 2019 were reviewed to identify patients diagnosed with TAB+ GCA. Incidence rates based on the 23-year period and the point-prevalence at 31 December 2014 were determined. An alternative prevalence calculation included only TAB+ GCA patients living in the study area and receiving immunosuppressant therapy on the point-prevalence date. Results: One thousand three hundred and sixty patients were diagnosed with TAB+ GCA (71% female). The average annual incidence 1997-2019 was 13.3 (95% CI: 12.6, 14.0) per 100 000 inhabitants aged ≥50 years and was higher in females (17.8; 95% CI: 16.7, 18.9) than in males (8.2; 95% CI: 7.4, 9.0). The age- and sex-standardized incidence declined from 17.3 in 1997 to 8.7 in 2019, with incidence ratio (IR) of 0.98 per year (95% CI: 0.98, 0.99). A seasonal variation was observed with higher incidence during spring than winter [IR = 1.19 (95% CI: 1.03, 1.39)]. The overall point-prevalence of TAB+ GCA was 127.1/100 000 (95% CI: 117, 137.3) and was 75.5 (95% CI: 67.7, 83.3) when including only patients receiving immunosuppressants. Conclusion: Over the past 2 decades, the incidence of biopsy-confirmed GCA has decreased by ∼2% per year. Still, a high prevalence of GCA on current treatment was observed. More cases are diagnosed during spring and summer than in the winter. © 2021 The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology.en
dc.language.isoenen
dc.sourceRheumatology (United Kingdom)en
dc.source.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85125013713&doi=10.1093%2frheumatology%2fkeab269&partnerID=40&md5=b7730f3682b4279bf67e5516eaac3fd7
dc.subjectdisease modifying antirheumatic drugen
dc.subjectglucocorticoiden
dc.subjectimmunosuppressive agenten
dc.subjectadulten
dc.subjectageden
dc.subjectArticleen
dc.subjectbiopsyen
dc.subjectblood vessel biopsyen
dc.subjectcontrolled studyen
dc.subjectfemaleen
dc.subjectgiant cell arteritisen
dc.subjecthistopathologyen
dc.subjecthumanen
dc.subjecthuman tissueen
dc.subjectimmunosuppressive treatmenten
dc.subjectincidenceen
dc.subjectmajor clinical studyen
dc.subjectmaleen
dc.subjectpoint prevalenceen
dc.subjectprevalenceen
dc.subjectseasonal variationen
dc.subjectspringen
dc.subjectSwedenen
dc.subjectwinteren
dc.subjectbiopsyen
dc.subjectgiant cell arteritisen
dc.subjectmiddle ageden
dc.subjectSwedenen
dc.subjectAgeden
dc.subjectBiopsyen
dc.subjectFemaleen
dc.subjectGiant Cell Arteritisen
dc.subjectHumansen
dc.subjectIncidenceen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectPrevalenceen
dc.subjectSwedenen
dc.subjectOxford University Pressen
dc.titleEpidemiology of biopsy-confirmed giant cell arteritis in southern Sweden - an update on incidence and first prevalence estimateen
dc.typejournalArticleen


Dateien zu dieser Ressource

DateienGrößeFormatAnzeige

Zu diesem Dokument gibt es keine Dateien.

Das Dokument erscheint in:

Zur Kurzanzeige